Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore

NCT ID: NCT07176130

Last Updated: 2025-09-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-19

Study Completion Date

2025-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a retrospective study analyzing demographics, clinical characteristics, treatment received, and outcomes of ocular inflammatory diseases that presented to the Singapore National Eye Centre (SNEC).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a retrospective, cross-sectional study. In this study, the investigators aim to investigate demographics, clinical characteristics, treatment received, and outcomes of ocular inflammatory diseases, including masquerade syndromes such as ocular neoplasms (e.g., vitreoretinal and uveal lymphoma) and endophthalmitis that presented to the Singapore National Eye Centre (SNEC). Data on demographics, clinical features, diagnosis, investigations, secondary complications, treatment received, and outcomes will be analyzed using statistical software. The results of this study will lead to an improved clinical practice with better treatment selections and an optimized monitoring protocol for follow-up care for patients with ocular inflammatory diseases, including masquerade syndromes such as ocular neoplasms (e.g.,vitreoretinal and uveal lymphoma) and endophthalmitis. This will lead to better clinical outcomes and prevention of serious sight-threatening complications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uveitis Scleritis and Episcleritis Endophthalmitis Masquerade Syndromes Intraocular Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Uveitis

Patients diagnosed with uveitis at Singapore National Eye Centre

No Intervention: Observational Cohort

Intervention Type OTHER

Not applicable, No intervention. Observational study.

Scleritis and Episcleritis

Patients diagnosed with scleritis or episcleritis at Singapore National Eye Centre

No Intervention: Observational Cohort

Intervention Type OTHER

Not applicable, No intervention. Observational study.

Intraocular lymphoma

Patients diagnosed with ocular neoplasms at Singapore National Eye Centre

No Intervention: Observational Cohort

Intervention Type OTHER

Not applicable, No intervention. Observational study.

Endophthalmitis

Patients diagnosed with endophthalmitis at Singapore National Eye Centre

No Intervention: Observational Cohort

Intervention Type OTHER

Not applicable, No intervention. Observational study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No Intervention: Observational Cohort

Not applicable, No intervention. Observational study.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with uveitis
* Patients diagnosed with scleritis or episcleritis
* Patients diagnosed with ocular neoplasms e.g., vitreoretinal and uveal lymphoma
* Patients diagnosed with endophthalmitis
* Diagnosis confirmed by laboratory testing or histopathological examination
* Patients diagnosed and managed at the Singapore National Eye Centre (SNEC)

Exclusion Criteria

* Patients with less than two years of clinical follow-up
* Patients with incomplete diagnostic confirmation (i.e., lacking laboratory or histopathological evidence)
* Patients diagnosed outside of Singapore National Eye Centre (SNEC)
* Cases with missing key clinical or outcome data
Minimum Eligible Age

21 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Singapore National Eye Centre

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Samanthila Waduthantri

Principal Resident Physician

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Singapore National Eye Centre

Singapore, , Singapore

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Singapore

References

Explore related publications, articles, or registry entries linked to this study.

Siak J, Jansen A, Waduthantri S, Teoh CS, Jap A, Chee SP. The Pattern of Uveitis among Chinese, Malays, and Indians in Singapore. Ocul Immunol Inflamm. 2017;25(sup1):S81-S93. doi: 10.1080/09273948.2016.1188968. Epub 2016 Jul 15.

Reference Type BACKGROUND
PMID: 27419535 (View on PubMed)

Chee SP, Jap A. Endogenous endophthalmitis. Curr Opin Ophthalmol. 2001 Dec;12(6):464-70. doi: 10.1097/00055735-200112000-00012.

Reference Type BACKGROUND
PMID: 11734687 (View on PubMed)

International Vitreoretinal B-Cell Lymphoma Registry Investigator Group. Presentation, Diagnostic Testing and Initial Treatment of Vitreoretinal Lymphoma. Ophthalmol Retina. 2024 Jan;8(1):72-80. doi: 10.1016/j.oret.2023.08.012. Epub 2023 Aug 28.

Reference Type BACKGROUND
PMID: 37648063 (View on PubMed)

Carbonell D, Mahajan S, Chee SP, Sobolewska B, Agrawal R, Bulow T, Gupta V, Jones NP, Accorinti M, Agarwal M, Batchelor T, Biswas J, Cimino L, tenDam-van Loon NH, de-la-Torre A, Frenkel S, Pe'er J, Kramer M, Miserocchi E, Mochizuki M, Ness T, Rosenbaum JT, Sen HN, Simion M (VRL patient), Sitter H, Vasconcelos-Santos DV, Habot-Wilner Z, Coupland SE, Pulido JS, Smith J, Thorne JE, Zierhut M; Study Group for Vitreoretinal Lymphoma Diagnostics. Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma. Ocul Immunol Inflamm. 2021 Apr 3;29(3):507-520. doi: 10.1080/09273948.2021.1878233. Epub 2021 May 19.

Reference Type BACKGROUND
PMID: 34009095 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019/2811

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

China Red Eye Study
NCT03814863 COMPLETED
Wide Field OCTA in Ocular Diseases
NCT07298174 NOT_YET_RECRUITING
Imaging Quantification of Inflammation (IQI)
NCT04704609 ACTIVE_NOT_RECRUITING
Clinical Outcome in Uveitis
NCT01983488 COMPLETED